dast track designation

Repligen soon will begin a first-ever human trial of a drug created specifically for spinal muscular atrophy;  FDA grants fast track designation

posted on May 20, 2011 - 11:13am
In a historic first, biotech company Repligen Corp., of Waltham, Mass., has received approval from the U.S. Food and Drug Administration (FDA) to begin a phase 1 clinical trial of the experimental drug RG3039 for spinal muscular atrophy (SMA).

New content is being added every day. Please check back again.